Background/Aims: The development of multidrug resistance (MDR), which results in disease recurrence and metastasis, is a crucial obstacle to successful chemotherapy for patients with gastric cancer (GC). Long non-coding RNAs (lncRNAs) have been found to play various roles in cancer. This study aimed to investigate the effect of XLOC_006753 on the development of MDR in GC cells. Methods: The expression levels of XLOC_006753 in GC patients and MDR GC cell lines (SGC-7901/5-FU and SGC-7901/DDP cell line) were assessed by qRT-PCR. Statistical analyses were conducted to determine the relationship between XLOC_006753 expression and clinical features and to assess the prognostic value of XLOC_006753 for overall survival and progression-free survival. Then, a CCK-8 assay was used to detect cell proliferation ability and chemosensitivity. Flow cytometry was used to detect cell cycle and cell apoptosis. A wound-healing assay and transwell assay were used to detect cell migration. The expression of markers for MDR, G1/S transition, epithelial-mesenchymal transition (EMT) and PI3K/ AKT/mTOR signaling pathway were examined by western blot. , and its high expression was positively associated with metastasis, TNM stage, tumor size, and poor survival in GC patients. Moreover, XLOC_006753 was an independent prognostic biomarker of overall survival and progression-free survival for gastric cancer patients. Knocking down XLOC_006753 in the two MDR GC cell lines significantly inhibited cell proliferation, cell viability, cell cycle G1/S transition, and migration. XLOC_006753 knockdown also promoted apoptosis. Furthermore, western blots showed that XLOC_006753 knockdown decreased some markers of MDR, G1/S transition, and EMT expression, while increasing caspase9 expression and inhibiting the PI3K/AKT/mTOR signaling pathway in SGC-7901/5-FU and SGC-7901/DDP cells. Conclusion: High expression of XLOC_006753 promoted the development of MDR, which was activated by the PI3K/AKT/mTOR pathway in GC cells.
Introduction
Gastric cancer (GC) is one of the most common malignancies of human digestive systems, and its high incidence is associated with high mortality rates globally [1] [2] [3] . Chemotherapy is usually used in the treatment of gastric cancer both in adjuvant and advanced settings [4] . Although chemotherapy has improved the survival of patients with gastric cancer, the development of multidrug resistance (MDR) is still a crucial problem leading to therapeutic failure and cancer-related death [5] . In addition, the underlying molecular mechanisms of MDR in gastric cancer remain elusive.
Recent studies indicate that long non-coding RNAs (lncRNAs) play essential roles in MDR. For example, lncRNAs, including GHET1 [6] , UCA1 [7, 8] , ANRIL [9] , and PVT1 [10] , are related to the development of MDR in GC. Furthermore, recent research has characterized multiple molecular roles of regulatory lncRNAs in the PI3K/Akt/mTOR signaling pathway that are involved in cancer drug resistance. For example, lncRNA HOTALR regulates cisplatin resistance of GC through the PI3K/Akt and Wnt/β-catenin signaling pathways [11, 12] . In addition, Ma et al. found that lncRNA DANCR mediates cisplatin resistance in glioma cells by activating the AXL/PI3K/Akt/NF-κB signaling pathway [13] . Similarly, lncRNA UCA1 enhances drug resistance through the mTOR signaling pathway in breast cancer [14] and EGFR-mutant non-small cell lung cancer [15] .
In our study, a novel lncRNA XLOC_006753 was found to be aberrantly expressed in gastric carcinoma, and the expression of XLOC_006753 was associated with metastasis, TNM stage, and tumor size. In addition, XLOC_006753 was up-regulated in SGC-7901/5-FU and SGC-7901/DDP cells. Inhibition of XLOC_006753 using siRNA significantly reduced cell growth and migration and promoted cell apoptosis in SGC-7901/5-FU and SGC-7901/ DDP cells. In this study, we further analyzed the effect of XLOC_006753 expression on the development of multidrug resistance in gastric cancer.
Materials and Methods
Patient tissue samples and cell culture GC tumor tissues and corresponding normal tissues were acquired from 110 cases of patients diagnosed with GC at Sun Yat-Sen University Cancer Center (SYSUCC). This study was approved by the Research Ethics Committees of Sun Yat-Sen University Cancer Center, and written informed consent was obtained from all patients.
Human gastric adenocarcinoma cell line (SGC-7901), maintained in the Surgical Laboratory at Guangzhou Medical University, and the MDR variants SGC-7901/5-FU and SGC-7901/DDP were obtained and maintained in laboratory conditions as described previously [16, 17] . Wound healing assay Cells were seeded into six-well plates and transfected with the negative control siRNA-NC or siRNA-XLOC_006753 for 36 h. Then, the cells were serum-starved for 22 h and replenished with 10% fetal bovine serum RPMI-1640 medium. When the cells reached 100% confluence, an artificial wound was carefully created by scratching the confluent cell monolayer with a 200 μL pipette tip. The wound was imaged immediately at 0 h, and then 12 and 24 h later.
Western blotting
Total proteins extracts were obtained from cells using lysis buffer containing protease inhibitor, and protein concentrations were determined by BCA protein assay kit (KenGEN BioTECH, Nanjing, China). First, 30-μg protein samples were separated by SDS-PAGE and transferred to PVDF membranes. The membranes were blocked with 5% skimmed milk for 2 h at room temperature and incubated with anti-antibody at 4°C overnight. After being washed three times with TBST, the membranes were incubated with HRP-conjugated secondary antibodies (Cell Signaling Technology, Danvers, MA, USA) at room temperature for 2 h. β-Tubulin was used as an internal control. Protein expression was visualized using a chemiluminescence system (Tanon 5200, Tanon Science & Technology Co., Ltd., Shanghai, China).
Statistical analysis
SPSS software (version 20.0; IBM Corp., Armonk, NY, USA) was used for statistical analyses. Relative expression of XLOC_006753 in GC tissues and paired normal tissues were evaluated using paired-sample t-tests. Chi-squared or Fisher's exact tests were used to examine the association between XLOC_006753 expression and various clinicopathological variables. Survival rates were calculated using a KaplanMeier survival analysis. The Cox proportional hazard regression model was used to identify independent prognostic factors. Test results with P < 0.05 were considered statistically significant.
Results

XLOC_006753 is upregulated in GC tissues and MDR GC cell lines
The expression of XLOC_006753 was analyzed in 43 cases of GC patients by qRT-PCR, which was normalized using GAPDH as an internal control. XLOC_006753 expression was significantly up-regulated in tumor tissues compared to the paired normal tissues (P < 0.05; Fig. 1A ). To determine whether XLOC_006753 is involved in tumor progression in MDR gastric Expression levels were normalized to GAPDH mRNA. *P < 0.05, ****P < 0.0001 
XLOC_006753 is associated with poor prognosis and an independent prognostic factor in GC patients
To further explore the prognostic value of XLOC_006753 in GC patients, we analyzed overall survival (OS) and progression-free survival (PFS) of GC patients with high or low XLOC_006753 expression using the Kaplan-Meier method and Log-rank test. The 5-year OS and PFS of patients with high XLOC_006753 expression were only 38.13% and 42.87%, respectively, which were considerably shorter than those with low XLOC_006753 expression (63.71% and 69.28%, respectively; Fig. 2A and B). Thus, a high level of XLOC_006753 is significantly associated with poor prognoses of GC patients.
We further stratified GC patients according to TNM stage. Stage I-II patients with high XLOC_006753 levels have remarkably poorer OS and PFS than those with low XLOC_006753 levels ( Fig. 2C and D) , and stage III patients with high XLOC_006753 levels had significantly shorter OS than those with low expression levels. Moreover, stage III patients with high XLOC_006753 levels had remarkably poorer PFS than those with low expression levels ( Fig. 2E and F). It should be noted that there was a small sample size for stage I-II patients. No significant difference was seen between OS and PFS of patients with high and low Table 1 . Association between XLOC_006753 expression and clinical characteristics in GC: χ2 or Fisher's exact tests were used for P-value calculation. aPatients were divided into high and low XLOC_006753 expression groups using the median expression level as the cut-off point (1.0347). TNM, tumor-node-metastasis To determine whether XLOC_006753 is an independent prognostic factor in GC patients, we analyzed the relationship of XLOC_006753 expression and various clinicopathological parameters with patient survival using univariate and multivariate Cox proportional hazard models. Univariate analysis indicated that T stage, node status, metastasis, TNM stage, and XLOC_006753 expression are significant predictors for OS of GC patients (Table 2) . Moreover, T stages, lymph node status, metastasis, and TNM stage are also significant predictors for PFS in GC patients, and XLOC_006753 is a significant predictor for OS and PFS in GC patients. Multivariate Cox regression analysis demonstrated that XLOC_006753 is an independent risk predictor for OS (HR, 2.333; 95% CI, 1.229-4.428, P = 0.010) in GC patients, but not for PFS (Table 2 ). These results suggest that XLOC_006753 is a potential biomarker for predicting the overall survival of GC patients. 
XLOC_006753 promotes cell proliferation and viability in MDR GC cells
To assess the biological significance of XLOC_006753 in MDR GC cells, we transfected SGC-7901/5-FU and SGC-7901/DDP cells with two XLOC_006753 siRNAs and one control siRNA-NC. The efficiency of siRNA-mediated XLOC_006753 knockdown was evaluated by qRT-PCR, achieving a significant reduction of XLOC_006753 (Fig. 3A and B) . A CCK-8 cell proliferation assay was also performed. XLOC_006753 siRNAs, but not negative control siRNA, significantly reduced proliferation of SGC-7901/5-FU and SGC-7901/DDP (Fig. 3C  and D) . These results indicate that XLOC_006753 is important to MDR GC cell proliferation. Then, after the SGC-7901/5-FU and SGC-7901/DDP cell lines were transfected with siRNA-XLOC_006753 or siRNA-NC for 24 h, these cells and SGC-7901 cells were treated with 5 μg/ml 5-FU or 2 μg/ml DDP for another 48 h, followed by a CCK-8 cell viability assay. SGC-7901/5-FU and SGC-7901/DDP cells transfected with siRNA-XLOC_006753 had a low viability that was similar to that of SGC7901, which suggested that XLOC_006753 knockdown reduced cell viability of SGC-7901/5-FU and SGC-7901/DDP cells (Fig. 3E) .
To investigate the mechanism by which XLOC_006753 enhances the drug resistance of GC cells, we examined the protein levels of several MDR-related proteins (MDR1, LRP1 and BCRP) by western blot. We found that the protein levels of MDR1, LRP1, and BCRP decreased in SGC-7901/5-FU and SGC-7901/DDP cells transfected with siRNA-XLOC_006753 compared to the control (Fig. 3F) .
XLOC_006753 promotes G1/S cell cycle progression in MDR GC cells through the G1/S pathway
Because XLOC_006753 knockdown inhibits MDR of GC cells, we further investigated whether the cell cycle is affected by XLOC_006753 knockdown. Flow cytometry analysis shows that XLOC_006753 downregulation significantly increases G1 cell population while decreasing S cell population in SGC-7901/5-FU cells (Fig. 4A and B) . A similar result was 
XLOC_006753 inhibits apoptosis in MDR GC cells by altering expression of apoptosisassociated proteins
The effect of XLOC_006753 knockdown on the apoptosis of SGC-7901/5-FU and SGC-7901/DDP cells was determined by flow cytometric analysis with Annexin V-FITC and PI double staining. Compared with SGC-7901/5-FU-siRNA-NC (2.34%) and SGC-7901/DDPsiRNA-NC cells (8.83%), the number of apoptotic cells was significantly increased in the SGC-7901/5-FU-siRNA 1 (11.97%), SGC-7901/5-FU-siRNA 2 (7.02%), SGC-7901/DDP-siRNA 1 (10.3%), and SGC-7901/DDP-siRNA 2 (18.8%) (Fig. 5A-D) . Next, we used immunoblotting analysis to monitor expression changes in apoptosis-associated proteins in SGC-7901/5-FU and SGC-7901/DDP cells with ablation of XLOC_006753. When compared with control cells, caspase9 protein levels were increased (Fig. 5E) . These results revealed that XLOC_006753 overexpression promoted apoptosis in SGC-7901/5-FU and SGC-7901/DDP cells by inhibiting expression of caspase9.
XLOC_006753 promotes migration in MDR GC cells through enhancing epithelialmesenchymal transition (EMT)
We also investigated the potential role of XLOC_006753 in cell migration using transwell and wound healing assays. In the transwell assay, down-regulation of XLOC_006753 significantly reduced the number of migrated cells for SGC-7901/5-FU and SGC-7901/DDP cells by approximately 60% and 45%, respectively (Fig. 6A ). In the wound healing assay, cell Fig. 6B  and C) . The EMT was also investigated in the migration inhibition in MDR caused by XLOC_006753 knock down. Western blot analysis was performed to determine the expression of EMT markers. We found that the expression of β-catenin, Vimentin, and Snail were reduced in SGC-7901/5-FU and SGC-7901/DDP cells in association with XLOC_006753 knockdown (Fig. 6D ). These results demonstrate that XLOC_006753 down-regulation inhibits the EMT.
XLOC_006753 promotes MDR by activation of the PI3K/AKT/mTOR signaling pathway
To determine whether the PI3K/AKT/mTOR signaling pathway was affected by XLOC_006753, the expression levels of PI3K, Akt, p-Akt, mTOR, p-mTOR, P70 S6 kinase, p-P70 S6 kinase, S6, p-S6, 4E-BP1, and p-4E-BP1 were analyzed by western blot. As shown in Fig. 7A , the expression levels of PI3K, p-AKT (Thr308), p-AKT (Ser473), p-mTOR (Ser2448), P70 S6 kinase/p-P70 S6 kinase (Thr389), p-S6 (Ser235/236), and p-4E-BP1 (Thr37/46) were reduced by siRNA-XLOC_006753 transfection. 
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Based on these reduced expression levels, XLOC_006753 may regulate acquired MDR in GC cells by increasing proliferation and growth, inhibiting apoptosis, and promoting metastasis. The abnormal expression of XLOC_006753 increased activation of the PI3K/Akt/ mTOR signaling pathway to promote drug resistance (Fig. 7B) .
Discussion
Growing evidence has implicated lncRNAs in a wide range of biological functions, and more and more lncRNAs have been identified as new prognostic markers of GC with potential uses in clinical diagnosis and prognostic evaluation [18] [19] [20] [21] . In the present study, we have detected the expression of XLOC_006753 in 110 cases of GC patients and found that the expression of XLOC_006753 in 36 GC tissues was significantly higher than that in paracancerous tissues. The expression of XLOC_006753 had no association with the sex, age, topography, lymph node status, family medical history, smoking, drinking, or tumor differentiation of patients. However, expression level was significantly associated with metastasis, TNM stage, and tumor size. Furthermore, XLOC_006753 is an independent predictive factor for OS, suggesting that XLOC_006753 is a potential biomarker for GC patient prognoses.
Recent studies have suggested that lncRNAs are associated with the regulation of important characteristics of cancer, including proliferation, apoptosis, metastasis, and drug resistance [22] [23] [24] [25] [26] . For example, lncRNA AKHE promotes tumor progression in hepatocellular carcinoma (HCC) via activation of NOTCH2 signaling [27] . Overexpression of lncRNA IGFBP4-1 reprograms energy metabolism to promote lung cancer (LC) cell proliferation and metastasis and inhibits apoptosis [28] . Similarly, lncRNA LINC01296 overexpression upregulates the expression of MYCN and promotes cell viability, migration, and invasion in human cholangiocarcinoma (CCA) cells [29] . Furthermore, Liang et al. reported that lncRNA LINP1 is upregulated in doxorubicin-and 5-fluorouracil-resistant cells and induced chemoresistance, indicating LINP1 is a potential therapeutic target and may be key to reducing chemoresistance in breast cancer (BC) [30] . Wen et al. showed that lncRNA GAS5 could influence cisplatin resistance in cervical cancer (CC) by regulating the phosphorylation of Akt [31] . Xue et al. found that lncRNA HOTAIR is upregulated in tamoxifen-resistant BC tissues; its overexpression increased BC cell proliferation and conferred tamoxifen resistance in BC [32] . In this study, we found that XLOC_006753 was upregulated in MDR GC cell lines; its knockdown significantly inhibited cell proliferation, cell cycle, cell viability, and metastasis and induced apoptosis in MDR GC cells. Therefore, we conclude that overexpression of XLOC_006753 promotes tumor progression in MDR GC cells.
To our knowledge, the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of the rapamycin (PI3K/AKT/mTOR) signaling pathway is one of the main growth regulatory pathways in both normal and cancer cells [33] . The PI3K/AKT/mTOR pathway regulates cell proliferation, differentiation, cellular metabolism, and cytoskeletal reorganization leading to apoptosis and cancer cell survival. Activation of the PI3K/AKT/ mTOR pathway mediated through molecular aberrations is instrumental in promoting tumor development as well as resistance to anticancer therapies [34, 35] . In our study, we investigated whether the expression level of XLOC_006753 was associated with tumor progression or MDR via the PI3K/AKT/mTOR pathway in GC cells. SGC-7901/5-FU and SGC-7901/DDP cells transfected with siRNA-XLOC_006753 exhibited decreased p-AKT, mTOR/p-mTOR, P70 S6K/p-P70 S6K, p-S6, and p-4E-BP1 expression, which suggests that chemotherapy resistance changes induced by XLOC_006753 might be mediated by the PI3K/ AKT/mTOR pathway. 
Conclusion
To date, lncRNA XLOC_006753 expression in cancers and its significance has not been reported. Our study shows that XLOC_006753 is up-regulated in GC and MDR GC cell lines. Furthermore, we demonstrate that overexpression of XLOC_006753 is able to promote multidrug resistance in gastric cancer by induction of cell proliferation, the cell cycle, and metastasis and reduction of apoptosis through the PI3K/AKT/mTOR pathway. This result indicates that XLOC_006753 knockdown may be a promising therapeutic strategy for GC MDR reversal.
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